Sponsors

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

To learn more, please visit us on www.Pfizer.com.sg and like us on Facebook at https://www.facebook.com/PfizerSG/.

Founded in 1839 in Melsungen, Germany, the family-owned company, B. Braun is one of the world’s leading suppliers of solutions for the healthcare market.    With over 66,000 employees in 64 countries, B. Braun provides users and patients with products and product systems for anesthesia, intensive care, cardiology, extracorporeal blood treatment, surgery for home care, as well as services for hospitals and general practitioners.

“Sharing Expertise” is our promise to develop effective solutions and create innovative standards in the field of healthcare through dialogue with our partners to protect and improve the health of people around the world.

A global leader in in vitro diagnostics for over 55 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. The company is present in 44 countries and serves more than 160 countries through the support of a large network of distributors.

bioMérieux develops and produces in vitro diagnostic solutions (systems, reagents, software and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample provide doctors with information to support their decisions.

For 30 years, bioMérieux has also applied the expertise acquired in the clinical sector to meeting industrial microbiology needs, making it possible to manage contamination risks in agri-food, pharmaceutical and cosmetic products, at each step of the production chain.

BioFire Diagnostics is the leader in syndromic infectious disease testing, with more than 25 years of molecular experience and as bioMérieux’s Global Center of Excellence for Molecular Diagnostics, BioFire sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing.

QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. We specialize in providing solutions for molecular diagnostics, applied testing, academic and pharmaceutical research and other fields. The company operates in over 25 countries worldwide and has a broad customer base that includes researchers, clinicians and other professionals.

One of QIAGEN’s flagship products is the QIAstat-Dx syndromic testing platform, a multiplexed molecular diagnostic system that enables rapid detection of a variety of pathogens linked to infectious diseases. QIAstat-Dx is designed to provide accurate and reliable results in about an hour, allowing for faster diagnosis and treatment of patients. The system uses proprietary technology that allows for simultaneous detection of multiple pathogens in a single sample, reducing the need for separate tests and saving time and resources.

QIAstat-Dx is highly user-friendly, with an intuitive touchscreen interface and minimal hands-on time. The system can support the work of clinicians in a variety of settings, including hospitals and clinics, and is ideal for situations where rapid diagnosis is essential. It is also highly flexible, with the ability to run a variety of different assays depending on the needs of the user. In May 2022, we announced the QIAstat-Dx Rise (coming soon) – a high-capacity version of the QIAstat-Dx.

Both platforms run on pre-packaged cartridges (panels) that contain all the necessary reagents and components to perform a particular assay. These panels are designed to provide fast, accurate and reliable detection of a variety of pathogens linked to infectious diseases, including respiratory infections, gastroenteritis and meningitis/encephalitis. This allows for faster diagnosis and treatment of patients, helping to improve patient outcomes and reduce the spread of infectious diseases.

To learn more about QIAstat-Dx, visit https://www.qiagen.com/qiastat-dx.